The impact of prolactin-raising antipsychotics on bone mineral density in patients with schizophrenia: Findings from a longitudinal observational cohort

Tatsuichiro Takahashi; Hiroyuki Uchida; Majnu John; Jinichi Hirano; Koichiro Watanabe; Masaru Mimura; Christoph U. Correll; Taishiro Kishimoto

doi:10.1016/j.schres.2013.04.015

The impact of prolactin-raising antipsychotics on bone mineral density in patients with schizophrenia: Findings from a longitudinal observational cohort

Tatsuichiro Takahashi, Hiroyuki Uchida, Majnu John, Jinichi Hirano, Koichiro Watanabe, Masaru Mimura, Christoph U. Correll, Taishiro Kishimoto

Department of Psychiatry

Research output: Contribution to journal › Article

23 Citations (Scopus)

Abstract

To examine the effect of prolactin-raising antipsychotics on bone mineral density (BMD), data of 164 schizophrenia patients who received ?. 2 dual-energy x-ray absorptiometry scans were analyzed (49.3% men; mean. ±. SD age: 58.5. ±. 11.0. years; duration of treatment: 26.7. ± 13.8. years). Patients were divided into a prolactin-raising antipsychotic (n = 141) or prolactin-sparing (n = 23) group, and time x group interaction was examined using mixed effect model. Although the BMD difference did not reach significance over 3.4. ± 1.6. years, a significant antipsychotic-class vs. time interaction was found (p = 0.011), indicating a negative impact of prolactin-raising antipsychotics on BMD. Large-scale, randomized-controlled data are required to replicate and extend these findings.

Original language	English
Pages (from-to)	383-386
Number of pages	4
Journal	Schizophrenia Research
Volume	147
Issue number	2-3
DOIs	https://doi.org/10.1016/j.schres.2013.04.015
Publication status	Published - 2013 Jul 1

Keywords

Antipsychotics
Bone mineral density
Dual-energy x-ray absorptiometry
Prolactin
Schizophrenia

ASJC Scopus subject areas

Psychiatry and Mental health
Biological Psychiatry

Access to Document

10.1016/j.schres.2013.04.015

Fingerprint Dive into the research topics of 'The impact of prolactin-raising antipsychotics on bone mineral density in patients with schizophrenia: Findings from a longitudinal observational cohort'. Together they form a unique fingerprint.

Cite this

Takahashi, T., Uchida, H., John, M., Hirano, J., Watanabe, K., Mimura, M., Correll, C. U., & Kishimoto, T. (2013). The impact of prolactin-raising antipsychotics on bone mineral density in patients with schizophrenia: Findings from a longitudinal observational cohort. Schizophrenia Research, 147(2-3), 383-386. https://doi.org/10.1016/j.schres.2013.04.015

The impact of prolactin-raising antipsychotics on bone mineral density in patients with schizophrenia : Findings from a longitudinal observational cohort. / Takahashi, Tatsuichiro; Uchida, Hiroyuki; John, Majnu; Hirano, Jinichi; Watanabe, Koichiro; Mimura, Masaru; Correll, Christoph U.; Kishimoto, Taishiro.

In: Schizophrenia Research, Vol. 147, No. 2-3, 01.07.2013, p. 383-386.

Research output: Contribution to journal › Article

Takahashi, Tatsuichiro ; Uchida, Hiroyuki ; John, Majnu ; Hirano, Jinichi ; Watanabe, Koichiro ; Mimura, Masaru ; Correll, Christoph U. ; Kishimoto, Taishiro. / The impact of prolactin-raising antipsychotics on bone mineral density in patients with schizophrenia : Findings from a longitudinal observational cohort. In: Schizophrenia Research. 2013 ; Vol. 147, No. 2-3. pp. 383-386.

@article{528e0376ea3942f68433d1dabfb03051,

title = "The impact of prolactin-raising antipsychotics on bone mineral density in patients with schizophrenia: Findings from a longitudinal observational cohort",

abstract = "To examine the effect of prolactin-raising antipsychotics on bone mineral density (BMD), data of 164 schizophrenia patients who received ?. 2 dual-energy x-ray absorptiometry scans were analyzed (49.3% men; mean. ±. SD age: 58.5. ±. 11.0. years; duration of treatment: 26.7. ± 13.8. years). Patients were divided into a prolactin-raising antipsychotic (n = 141) or prolactin-sparing (n = 23) group, and time x group interaction was examined using mixed effect model. Although the BMD difference did not reach significance over 3.4. ± 1.6. years, a significant antipsychotic-class vs. time interaction was found (p = 0.011), indicating a negative impact of prolactin-raising antipsychotics on BMD. Large-scale, randomized-controlled data are required to replicate and extend these findings.",

keywords = "Antipsychotics, Bone mineral density, Dual-energy x-ray absorptiometry, Prolactin, Schizophrenia",

author = "Tatsuichiro Takahashi and Hiroyuki Uchida and Majnu John and Jinichi Hirano and Koichiro Watanabe and Masaru Mimura and Correll, {Christoph U.} and Taishiro Kishimoto",

year = "2013",

month = jul,

day = "1",

doi = "10.1016/j.schres.2013.04.015",

language = "English",

volume = "147",

pages = "383--386",

journal = "Schizophrenia Research",

issn = "0920-9964",

publisher = "Elsevier",

number = "2-3",

}

TY - JOUR

T1 - The impact of prolactin-raising antipsychotics on bone mineral density in patients with schizophrenia

T2 - Findings from a longitudinal observational cohort

AU - Takahashi, Tatsuichiro

AU - Uchida, Hiroyuki

AU - John, Majnu

AU - Hirano, Jinichi

AU - Watanabe, Koichiro

AU - Mimura, Masaru

AU - Correll, Christoph U.

AU - Kishimoto, Taishiro

PY - 2013/7/1

Y1 - 2013/7/1

N2 - To examine the effect of prolactin-raising antipsychotics on bone mineral density (BMD), data of 164 schizophrenia patients who received ?. 2 dual-energy x-ray absorptiometry scans were analyzed (49.3% men; mean. ±. SD age: 58.5. ±. 11.0. years; duration of treatment: 26.7. ± 13.8. years). Patients were divided into a prolactin-raising antipsychotic (n = 141) or prolactin-sparing (n = 23) group, and time x group interaction was examined using mixed effect model. Although the BMD difference did not reach significance over 3.4. ± 1.6. years, a significant antipsychotic-class vs. time interaction was found (p = 0.011), indicating a negative impact of prolactin-raising antipsychotics on BMD. Large-scale, randomized-controlled data are required to replicate and extend these findings.

AB - To examine the effect of prolactin-raising antipsychotics on bone mineral density (BMD), data of 164 schizophrenia patients who received ?. 2 dual-energy x-ray absorptiometry scans were analyzed (49.3% men; mean. ±. SD age: 58.5. ±. 11.0. years; duration of treatment: 26.7. ± 13.8. years). Patients were divided into a prolactin-raising antipsychotic (n = 141) or prolactin-sparing (n = 23) group, and time x group interaction was examined using mixed effect model. Although the BMD difference did not reach significance over 3.4. ± 1.6. years, a significant antipsychotic-class vs. time interaction was found (p = 0.011), indicating a negative impact of prolactin-raising antipsychotics on BMD. Large-scale, randomized-controlled data are required to replicate and extend these findings.

KW - Antipsychotics

KW - Bone mineral density

KW - Dual-energy x-ray absorptiometry

KW - Prolactin

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=84879004266&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879004266&partnerID=8YFLogxK

U2 - 10.1016/j.schres.2013.04.015

DO - 10.1016/j.schres.2013.04.015

M3 - Article

C2 - 23668975

AN - SCOPUS:84879004266

VL - 147

SP - 383

EP - 386

JO - Schizophrenia Research

JF - Schizophrenia Research

SN - 0920-9964

IS - 2-3

ER -